article thumbnail

Revised for 2021 — NORML Report Highlights Over 450 Studies Assessing the Therapeutic Efficacy of Cannabis and Cannabinoids

NORML

This updated edition reviews over 450 peer-reviewed studies assessing the safety and efficacy of either whole-plant cannabis or cannabinoids for 23 different patient populations.

article thumbnail

United States Minor Cannabinoids (CBG, CBC, CBN, THCV, CBGA) Markets Report 2021-2028 – ResearchAndMarkets.com

Cannabis Law Report

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK: Assoc For The Cannabinoid Industry Founder Says UK World’s Biggest Market After The US

Cannabis Law Report

Such products will generate sales of £690 million ($856 million, 811 million euros) in 2021, according to the Association for the Cannabinoid Industry (ACI). Britain’s Food Standards Agency now regulates the sector and its marketing, after the European Union classified CBD as food in 2019.

article thumbnail

Answer of the Day for Jul 23, 2021

TheAnswerPage

Some cannabinoid-based drugs have been approved by national drug administrations. Other than seizure disorders, what are the therapeutic indications for cannabinoid-based medicines that have been approved by a national drug administration? e58010716930, 2021. GONZAGA, R. Medicinal uses of Cannabis sp. DOI: 10.3344.

article thumbnail

Answer of the Day for Jul 6, 2021

TheAnswerPage

There is a high strength of evidence for the efficacy of cannabinoid-based medicines for the treatment of intractable epilepsy, multiple sclerosis and cancer-related nausea. Which of these 3 conditions has the greatest relative number of patients using cannabinoid -based medicines to treat the condition? Schlag, A.K.,

article thumbnail

Answer of the Day for Aug 20, 2021

TheAnswerPage

Has any national drug administration approved a CBD-containing product for therapeutic use in conditions other than epilepsy? Regulatory approval has been obtained in numerous countries outside the United States for the treatment of multiple sclerosis symptoms (nerve pain, spasticity, overactive bladder, and other symptoms).

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

Commenting on the MHRA approval of GW’s cannabidiol, Tuberous Sclerosis Association (TSA) Chief Executive Louise Fish said: “One in every two people living with TSC-related epileptic seizures has difficult to treat epilepsy that does not respond to traditional anti-epileptic drugs. GW was acquired by Jazz Pharmaceuticals in May 2021.